5O0F

Crystal structure of Phosphopantetheine adenylyltransferase from Mycobacterium abcessus in complex with 3-(indol-3-yl)propanoic acid (Fragment 5)

5O0F の概要

• エントリーDOI: 10.2210/pdb5o0f/pdb
• 分子名称: Phosphopantetheine adenylyltransferase, INDOLYLPROPIONIC ACID (3 entities in total)
• 機能のキーワード: coenzyme a biosynthesis, transferase
• 由来する生物種: Mycobacterium abscessus ATCC 19977
• 細胞内の位置: Cytoplasm : B1MDL6
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 52809.08

構造登録者

Thomas, S.E.,Kim, S.Y.,Mendes, V.,Blaszczyk, M.,Blundell, T.L. (登録日: 2017-05-16, 公開日: 2017-06-28, 最終更新日: 2024-01-17)

主引用文献

Thomas, S.E.,Mendes, V.,Kim, S.Y.,Malhotra, S.,Ochoa-Montano, B.,Blaszczyk, M.,Blundell, T.L.
Structural Biology and the Design of New Therapeutics: From HIV and Cancer to Mycobacterial Infections: A Paper Dedicated to John Kendrew.
J. Mol. Biol., 429:2677-2693, 2017

PubMed Abstract: Interest in applications of protein crystallography to medicine was evident, as the first high-resolution structures emerged in the 50s and 60s. In Cambridge, Max Perutz and John Kendrew sought to understand mutations in sickle cell and other genetic diseases related to hemoglobin, while in Oxford, the group of Dorothy Hodgkin became interested in long-lasting zinc-insulin crystals for treatment of diabetes and later considered insulin redesign, as synthetic insulins became possible. The use of protein crystallography in structure-guided drug discovery emerged as enzyme structures allowed the identification of potential inhibitor-binding sites and optimization of interactions of hits using the structure of the target protein. Early examples of this approach were the use of the structure of renin to design antihypertensives and the structure of HIV protease in design of AIDS antivirals. More recently, use of structure-guided design with fragment-based drug discovery, which reduces the size of screening libraries by decreasing complexity, has improved ligand efficiency in drug design and has been used to progress three oncology drugs through clinical trials to FDA approval. We exemplify current developments in structure-guided target identification and fragment-based lead discovery with efforts to develop new antimicrobials for mycobacterial infections.

PubMed: 28648615
DOI: 10.1016/j.jmb.2017.06.014

実験手法

X-RAY DIFFRACTION (1.704 Å)